



## REFERENCE

*Abdel-Aziz, F.; Mohamed, M.K.; Abdel-Hamid, M.; et al., (2000):* HCV infection in a community in the Nile Delta: population description and HCV prevalence. *Hepatology*; 32: 111-115.

*Abdel-Hamid, M.; El-Daly, M.; El-Kafrawy, S.; et al., (2002):* Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. *J Clin Microbiol* 40:1656–1659.

*Abdoul, H; vincet ,M;sanistal,P; et al. (2008):* serum alpha fetoprotein predicts outcome of treatment of chronic HCV. *Pols One* 3(6): e2319.

*Ahmetagic, S.; Muminhodzic, K.; Cickusic, E.; et al., (2006):* Hepatitis C infection in risk groups. *Bosn J Basic Med Sci* 6: 13-7.

*Alter, M.J. (2002):* Prevention of spread of hepatitis C. *Hepatology* 36: S93-S98.

*Alter, M.J. (2007):* Epidemiology of hepatitis C virus infection. *World J Gastroenterol* May 7; 13(17): 2436-2441.

*Alter, M.J.; Kuhnert, W.L. and Finelli, L. (2003):* Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. *MMWR Recomm Rep.*; 52: 1-13, 15; quiz CE1–4.

*Amiri, Z.M.; Shakib, A.J. and Toorchi, M. (2005):* Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. *East Mediterr Health J* 11: 372-6. an update. *Swiss Med Wkly*; 131: 291- 298.

**Asselah, T.; Boyer, N.; Guimont, M.C.; et al., (2003):** Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. *Gut*. Nov; 52(11):1638-43.

**Atrah, H.A. and Ahmed, M.M. (1996):** Hepatitis C virus seroconversion by a third generation ELISA screening test in blood donors. *J clin Pathol*; 49:245-255.

**Bedossa, P. and Poynard, T. (1996):** An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology*; 24: 289-293.

**Bennett, C.L.; Silver, S.M.; Djulbegovic, B.; et al., (2008):** Venous thrombo-embolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer associated anemia. *Jama*; 299: 914-924.

**Bergman, S.; Accortt, N.; Turner, A.; et al., (2005):** Hepatitis C infection acquired pre-ESRD. *Am J Kidney Dis* Apr;45(4):684-9.

**Bernengo, M.G.; Quaglino, P. and Cappello, N. ( 2000):** Macrophage-mediated immuno stimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. *Melanoma Res*;10:55-65.

**Boniolo, A.; Dovis, M. and Mattega, R. (1982):** The use of enzyme-linked immunosorbent assay for screening hybridoma antibodies against hepatitis B surface antigen. *J Immunol Meth*, 49:1.

**Boyer, N. and Marcellin, P. (2000):** Pathogenesis, diagnosis and management of hepatitis C. *J Hepatol*; 32 (suppl 1): 98- 112.



**Bruix, J. and Sherman, M. (2005):** Management of hepatocellular carcinoma. *Hepatology*; 42: 1208-1236.

**Bruno, S.; Stroffolini, T.; Colombo, M.; et al., (2007):** SVR to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. *Hepatology*; 45: 579-587.

**Busch, M.P.; Glynn, S.A.; Stramer, S.L.; et al., (2005):** A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. *Transfusion* 45: 254-264.

**Castera, L.; Constant, A. and Bernard, P.H. (2006):** Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C. *Journal Of Viral Hepatitis* . 13(7):482-7.

**Cavalloro, I. I.; Palmer, D.F. and Bigazzi, P.E. (1996):** Immunofluorescence detection of autoimmune disease: Atlanta, US Dept., Health Education and Welfare, P. 128.

**Cedrone, A.M.; Covino, E.; Caturelli, et al., (2000):** Utility of AFP in the screening of patients with virus related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients, *Hepatogastroenterology*; 47: pp. 1654–1658.

**Charles, E. and Samuel, S. (2001):** Antiviral Actions of Interferons. *Clinical Microbiology Reviews*; Vol. 14,(4):778-809.

**Chen, TM ; Huang ,PT ; Tasi MH ; et al., (2007):** Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, *J Gastroenterol Hepatol*. 2007 May;22(5):669-75.



***Cheruvattath, R.; Rosati, M.J.; Gautam, M.; et al., (2007):*** Pegylated interferon and ribavirin failures: is retreatment an option? *Dig. Dis. Sci.*; 52: 732-736.

***Choo, Q.L.; Kuo, G.; Weiner, A.J.; et al., (1989):*** Isolation of a c DNA clone derived from a blood borne non-A, non-B viral hepatitis genome. *Science* 244 :359-362.

***Christiansen, M.; Høgdall, C.K. and Hogdall, E.V. (2000):*** "Alpha-fetoprotein in human fetal cerebrospinal fluid". *International journal of clinical chemistry*; 291 (1): 35–41.

***Chu, C.W.; Hwang, S.J.; Luo, J.C.; et al., (2001):*** Clinical, virologic and pathologic significance of elevated serum AFP levels in patients with chronic hepatitis C. *J. Clin. Gastroenterol.*; 32: 240–244.

***Comanor, L.; Anderson, F.; Ghany, M.; et al., (2001):*** Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. *Am J Gastroenterol* 96:2968–2972.

***Comanor, L.; Elkin, C.; Leung, K.; et al., (2003):*** Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay. *J Clin Virol* 28:14–26.

***Cornberg, M.; Hadem, J.; Herrmann, E.; et al., (2006):*** Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open label pilot study. *J. Hepatology*; 44: 291-301.

**Cotler, S.J.; Wartelle, C.F.; Larson, A.M.; et al., (2000):** Pretreatment symptoms and dosing regimen predict side effects of interferon therapy for hepatitis C. *J. Viral Hepat.*; 7: 211-217.

**Cupta, S.; Bent, S. and Kohlwes, J. (2003):** Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. a systematic review and critical-analysis, *mn inter Med* 139:46-50.

**Czaja, A.J. and Freese, D.K. (2002):** Diagnosis and treatment of autoimmune hepatitis. *Hepatology*; 36: 479-497.

**Davis, G. (1999):** Hepatitis C. In: Schiff 's Diseases of the Liver, 8th ed. Schiff ER, Sorrell M and Maddrey WC (eds.), Lippincott-Raven publishers, New York: p 793 – 836

**Del Rio, R.A.; Post, A.B. and Singer, M.E. (2006):** Cost effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. *Hepatology*; 44: 1598-1606.

**Deng, R. and Brook, K.V. (1994):** 5' and 3' untranslated regions of pestivirus genome: primary and a secondary structure analysis. *Nucleic Acid Res*; 21: 1949- 1957.

**Des Jarlais, D.C.; Diaz, T.; Perlis, T.; et al., (2003):** Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. *Am J Epidemiol* 157: 467-471.

**Deuffic-Burban, S.; Poynard, T.; Sulkowski, M.S.; et al., (2007):** Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. *J. Viral Hepat.*; 14: 107-115.

**Di Bisceglie, A.M.; Hoofnagle, J.H. and Krawczynski, K. (1993):** Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology; 105: 858- 862.

**Di Bisceglie, A.M.; Shiffman, M.L.; Everson, G.T.; et al., (2008):** Prolonged therapy of advanced chronic hepatitis C with low-dose peg-interferon. N. Engl. J. Med.; 359: 2429-2441.

**Di Bisceglie, A.M.; Sterling, R.K.; Chung, R.T.; et al., (2005):** serum AFP level in patients with chronic hepatitis. J hepatol 43:434-41.

**Dienstag, J.L. (2002):** The role of liver biopsy in chronic hepatitis C. Hepatology; 36(Suppl): S152-S160.

**Dubuisson, J. (2007):** "Hepatitis C virus proteins". World J. Gastroenterol. 13(17):2406-15.

**El-Amin, H.H.; Osman, E.M.; Mekki, M.O.; et al., (2007):** Hepatitis C virus infection in hemodialysis patients in Sudan: two centers' report. Saudi J Kidney Dis Transpl 18: 101-6.

**Elmowalid, G.A.; Qiao, M.; Jeong, S.H.; et al., (2007):** Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A. ;104(20):8427-32.

**Elrefaei, M.; El-sheikh, N.; Kamal, K. and Cao, H. (2004):** Analysis of T cell response against hepatitis C virus genotype 4 in Egypt. J HepatoL 40: 313- 318.

**El-Sadawy, M.; Ragab, H.; El-Toukhy, H.; et al., (2004):** hepatitis C virus infection at Sharkia Governorate , Egypt : seroprevalence and associated risk factors. J-Egypt-Soc-Parasitol. Apr; 34(1 Suppl):367-84.



**Eric, J.; Frank, G. and Haluska, L. (2001):** Interferon in Oncological Practice: Review of Interferon Biology , Clinical Applications, and Toxicities. *The Oncologist*; 6 (1): 34-55.

**Fattovich, G.; Giustina, G.; Almasio, P.; et al., (1997):** Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology*; 112: 463-472.

**Ferenci, P.; Formann, E.; Laferl, H.; et al., (2006):** Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. *J Hepatol.*; 44(2):275-82.

**Figlewicz, D.A.; Dellatre, O.; Guellaen, G.; et al., (2004):** Mapping of human  $\gamma$ -glutamyltranspeptidase on chromosome 22 and other human autosomes. *Genomics*; 17: 299-305.

**Folgori, A.; Capone, S.; Ruggeri, L.; et al., (2006):** A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. *Nat Med.*; 12(2):190-7.

**Fontaine, F.; Cardin, R.; Fiorentino, M.; et al., (2001):** Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. *J. Viral Hepat.*; 8: 34–40.

**Formann, E.P.; Steindl-Munda, H.; Hofer, et al., (2006):** Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. *Aliment. Pharmacol. Ther.*; 23: 507–511.

**Frank, C.; Mohamed, M.K.; Strickland, G.T.; et al., ( 2000 ) :** the role of parenteral antischistosomal therapy in spread of HCV in Egypt. *lancet*; 335:887-891.



**Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; et al., (2002):** Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N. Engl. J. Med.*; 347: 975-982.

**Gardner, J.P.; Durso, R.J.; Arrigale, R.R.; et al., (2003):** L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. *Proc Natl Acad Sci U S A.*; 100(8):4498-503.

**Ghany, G.; Marc, Doris B.; Strader, David L.; Thomas, et al., (2009):** Diagnosis, Management, and Treatment of Hepatitis C: An Update. *Hepatology*, April; 49: 1335-1374.

**Goldstein, D.L; Sielaff, K.M. and Storer, B.E. ( 1998):** Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. *J Natl Cancer Inst*;81:1061-1068.

**Gonzalez – Peralta, R.P.; Davis, G.L. and La, J.Y. (2005):** Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. *J Hepatol*; 21: 255- 259.

**Grakoui, A.; McCourt, D.W.; Wychowski, C.; et al., (1993):** second hepatitis C virus encoded proteinase. *Proc Natl Acad Sci*; 90: 10583-10587.

**Gavier, B ; Martínez-González, M A; Riezu-Boj , J I ; et al(1997):** Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C *Journal: Gastroenterology* ;11(5);1647-53.

**Habib, M.; Mohamed, M.; Abdel-aziz, F.; et al., (2001):** HCV infection in a community in the Nile Delta: *Hepatology*; 33: 284-253.

**Hadziyannis, S.J.; SetteHJr, Morgan T.R.; et al., (2004):** Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann. Intern. Med.*; 140: 346-355.

**Harris, J.; Kozlowski, A. ; Charles, S. and Milton, A. (2001):** Evaluation of the safety and efficacy of once-weekly PEG interferon in treatment of HCV. *J Gastroenterology*;120: 438-447.

**Hauri, A.M.; Armstrong, G.L. and Hutin, Y.J. (2004):** The global burden of disease attributable to contaminated injections given in health care settings. *Int J STD AIDS* 15: 7-16.

**Hino, K. and Okita, K. (2004):** Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. *J Antimicrob Chemother* Jan;53(1);19-22.

**Hoofnagle, J.H. (2002):** Course and Outcome of Hepatitis C. *Hepatology*; 36 (suppl 1): 21-29.

**Hwang, L.Y.; Kramer, J.R.; Troisi, C.; et al., (2006):** Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. *Hepatology* 44: 341-351.

**Idéo, G.; Bellobuono, A.; Tempini, S.; et al., (1999):** Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: A randomized, multicentre study. *Eur J Gastroenterol Hepatol.* ;11(11):1203-7.

**Ito, T.; Tahara, S.M and Lai, M.M. (1998):** The 3'- untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. *J Virol*; 72: 8789- 96.

**Jacobson, I.M.; Ahmed, F.; Russo, M.W.; et al., (2004):** Interferon alfa-2b [correction of alpha-2b] and ribavirin for patients with chronic hepatitis C and normal ALT. *Am. J. Gastroenterol.*; 99: 1700-1705.

**Jacobson, I.M.; Gonzalez, S.A.; Ahmed, F.; et al., (2005):** A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. *Am. J. Gastroenterol.*; 100: 2453-2462.

**Jacobson, J.M.; Feinman, L.; Liebes, L.; et al., (2001)** Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. *Antimicrob Agents Chemother.* ;45(2):517-24.

**Jacobson, K.R.; Murray, K.; Zellos, A. and Schwarz, K.B. (2002):** An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. *J Pediatr Gastroenterol Nutr*, 34:52.

**Jassam, N.; Jones, C.M.; Briscoe, T. and Horner, J.H. (2006):** "The hook effect: a need for constant vigilance". *Ann. Clin. Biochem.*; 43 (Pt 4): 314–317.

**Jonas, M.M. (1996):** Viral hepatitis. In: *Pediatric Gastrointestinal Disease*, 2<sup>nd</sup> ed. Craven L (ed.), Mosby, St Louis, Baltimore, Boston. Carlsbad, Chicago, Naples, New York, Philadelphia, Portland, London, Madrid, Mexico City, Singapore, Sydney, Tokyo, Toronto, Weistbaden, Vol. 2, Ch. 3:1028- 1051.

**Jonas, M.M. (2000):** Postnatal infections of the liver: viral hepatitis. In: *Pediatric Gastrointestinal Disease (pathophysiology, diagnosis and management)*, 3<sup>rd</sup> ed. Walker WA, Durie PR, Hamilton JR, Walker-Smith JA and Watkins JB (eds.). BC Decker, United States, Canada, Ch 55 (1): 939- 964.



**Kalantar-Zadeh, K.; Daar, E.S.; Eysselein, V.E.; et al., (2007):** Hepatitis C infection in dialysis patients: a link to poor clinical outcome?. *Int Urol Nephrol* 39:247–259.

**Kalantar-Zadeh, K.; McAllister, C.J.; Miller, L.G.; et al., (2006):** Hepatitis C virus and death risk in hemodialysis patients. *Am J Kid Dis* 47:B1–B18 (abstract 73, NKF Spring Clinical Meetings April 19–23, 2006, Chicago, IL).

**Kamal, S.; Madwar, M.; Bianchi, L.; et al., (2000):** Clinical, virological: long-term follow-up in patients with chronic HCV co-infected with *S. mansoni*. *Liver*, 20: 281: 290.

**Kamal, S.M. (2008):** “Acute hepatitis C:a systemic review”. *The American Journal of Gasenterology* 103(5):1283-97.

**Kamal, S.M.; El Kamary, S.S.; Shardell, M.D.; et al., (2007):** Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology*; 46: 1732-1740.

**Karmochkine, M.; Carrat, F.; Dos Santos, O.; et al., (2006):** “A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection”. *J. Viral Hepat.* 13(11):775-82.

**Kew, M.; Francois, G.; Lavanchy, D.; et al., (2004):** ”Prevention of hepatitis C virus infection”. *J Virol Hepat.* 11;198-205.

**Khan, N.; Aswad, S.; Shidban, H.; et al., (2004):** Improved detection of HCV infection in hemodialysis patients using a new HCV RNA qualitative assay: experience of a transplant center. *J Clin Virol* 30:175–182.



**Khien, V.V. (2001):** Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. *Int J Biol Markers* Apr-Jun; 16(2):105-11.

**Kieffer, T.L.; Sarrazin, C.; Miller, J.S.; et al., (2007):** Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. *Hepatology*; 46(3):631-9.

**Kinoshita, Y.; Tajiri, T.; Souzaki, R.; et al., (2008):** "Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study". *J. Pediatr. Hematol. Oncol.*; 30 (6): 447–450.

**Kleiner, D.E. (2005):** The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. *Semin Liver Dis.*; 25: 52-64.

**Kobayashi, S.; Takeda, T.; Enomoto, M.; et al., (2007):** Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int.*; 27:186-191.

**Kohn, I. (1956):** A new supporting medium for zone electrophoresis. *Biochem.* 65:9. Quoted from Crawford I (1991): Protein electrophoresis and immunofixation. In: *Practical Laboratory Hematology*, Koepke IA (ed.), Churchill Livingstone, New York, Edinburgh, London, Melbourne, Tokyo, Ch. (11): 237.

**Kolykhalov, A.A.; Feinstone, S.M. and Rice, C.M. (1996):** Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. *J Virol*; 70: 3363- 3371.

**Koziel, M.J. (1997) :** The role of immune responses in the pathogenesis of HCV infection. *J Viral hepat*; 4: 31: 34.



**Krajden, M.; Ziermann, R.; Khan, A.; et al., (2002):** Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. *J Clin Microbiol* 40:2903–2907.

**Kuzushita, N.; Gregory, S.H.; Monti, N.A.; et al., (2006):** Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. *Gastroenterology*; 130(2):453-64.

**La Torre, G.; Miel, L.; Southern, Lazio Collaborative Group, et al., (2006):** Correlates of HCV seropositivity among familial contacts of HCV positive patients. *BMC Public Health*. 6:237–245.

**Lauer, G.M. and Walker, B.D. (2001):** Hepatitis C virus infection *N Engl J med*; 345(1):41-52.

**Lawitz, E.J.; Hepburn, M.J. and Casey, T.J. (2004):** A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy *Am J Gastroenterol*. ;99(12):2359-64.

**Lazarevich, N.L. (2000):** Molecular mechanisms of alpha-fetoprotein gene expression. *Biochemistry (Mosc)*; 65: 117–133.

**Lee, W.M.; Dienstag, J.L.; Lindsay, K.L.; et al., (2004):** Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. *Control Clin. Trials*; 25: 472-492.

**Leerapun, A.; Suravarapu, S.; Bida, J.P.; et al., (2007):** The utility of serum AFP-L3 in the diagnosis of hepatocellular carcinoma: Evaluation in a U.S. referral population. *Clin Gastroenterol Hepatol*; 36: 87- 23.



**Lemon, S.M. and Honda, M. (1997):** Internal ribosome entry sites within the RNA genomes of hepatitis C virus and other flaviviruses. *Semin Virol*; 8: 274- 288.

**Levine, R.A.; Sanderson, S.O.; Ploutz-Snyder, R.; et al., (2006):** Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. *Clin. Gastroenterol. Hepatol*; 4: 1271-1277.

**Li, D. (2001):** AFP-L3 a new generation of tumor marker for hepatocellular carcinoma, *Clin Chim Acta*; 313(1-2):15-9.

**Lin, C.C.; Yeh, L.T.; Vitarella, D. and Hong, Z. (2003):** Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. *Antivir Chem Chemother.* ;14(3):145-52.

**Lui, Y.J. (2005):** Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors". *Annu Rev Immunol*; 23:299-306.

**Males, S.; Raafat Gad, R.; Esmat, G.; et al., (2007):** Serum alpha fetoprotein level predicts treatment outcome in chronic hepatitis C. *Antiviral Therapy*; 12: 797–803.

**Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; et al., (2001):** Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*; 358: 958-965.

**Mast, E.E.; Hwang, L.Y.; Seto, D.S.; et al., (2005):** Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis* 192: 1880-1889.



**McHutchison, J.G.; Dusheiko, G.; Shiffman, M.L.; et al., (2007):** Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N. Engl. J. Med.*; 357: 2227-2236.

**Medhat, A.; Shehata, M.; Abdel-Baki, L.; et al., (2002):** Hepatitis C in a community in Upper Egypt: risk factors for infection. *Am. J. Trop. Med. Hyg.*; 66: 633-638.

**Meyer-Olson, D.; Shoukry, N.H.; Brady, K.W.; et al., (2004):** Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. *J Exp Med.*; 200(3):307-19.

**Mohamed, M.K. (2004):** Epidemiology of HCV in Egypt 2004. *The Afro-Arab Liver Journal*, vol 3, No2, (July), pp 41-52.

**Mondelli, M.U. (2004):** Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts? Hepatitis C: An update. *Swiss Med Wkly*;40:536:538.

**Moradpour, Cerny A.; Heim, et al., (2001):** Hepatitis C: An update. *Swiss Med Wkly*; 131: 291: 298.

**Muñoz, A.E.; Levi, D.; Podestá, A.; et al., (2000):** Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial. *Gut.*; 46(3):427-31.

**Murphy, E.L.; Bryzman, S.M.; Glynn, S.A.; et al., (2000):** risk factors for hepatitis C virus infection in United States blood donors . NHLBI Retrovirus Epidemiology Donor Study (REDS). *Hepatology Mar*;31(3):756-62.



**Myers, T.W. and Gelfand, D.H. (1991):** Revers transcription and DNA amplification by thermophilus DNA polymerase. *Biochemistry*; 30: 7661-7666.

**Nafeh, M.; Medhat, A.; Shehata, M.; et al., (2000):** Hepatitis C in the community in upper Egypt: cross-sectional survey. *Am J trop Med Hyg*; 63:236-241.

**Nainan, O.V.; Alter, M.J.; Kruszon-Moran, D.; et al., (2006):** Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. *Gastroenterology*; 131: 478-484.

**Nelson, D.R.; Marousis, C.G. and Davis, G.L. (1997):** The role of hepatitis C virus – specific cytotoxic T lymphocytes in chronic hepatitis C. *J immunol*; 158: 1473.

**Nevens, F.; Roskams, T.; Van Vlierberghe, H.; et al., ( 2003):** A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. *Hepatology* ;38 (5):1289-96.

**Nguyen, M.H.; Trinh, H.N.; Garcia, R.; et al., (2008):** Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peg-interferon plus ribavirin. *Am. J. Gastroenterol.*; 103: 1131-1135

**Noiri, E.; Nakao, A.; Oya, A.; et al ., (2001):** Hepatitis C virus in blood and dialysate in haemodialysis. *Am J Kidney Dis Jan*;37(1):38-42.

**Ocak, S.; Duran, N.; Kaya, H. and Emir, I. (2006):** Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis. *Int J Clin Pract* 60: 670-4.



**Okuda, K. (2002):** Hepatocellular carcinoma. *J Hepatol*; 32 (Suppl 1):225-237

**Olynyk, J.K.; Reddy, K.R.; Di Bisceglie, A.M.; et al., (1996):** Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology*; 108: 1104-1109.

**Op De Beeck, A. and Dubuisson, J. (2003):** “Topology of hepatitis C virus envelope glycoproteins”. *Rev. Med. Virol.*13(4):233-41.

**Patton, H.M.; Patel, K.; Behling, C.; et al., (2004):** The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J. Hepatology*; 40: 484-490.

**Paul, S.B.; Gulati, M.S.; Sreenivas, V.; et al., (2007):** "Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein". *Oncology 72 Suppl.*; 1: 117–123.

**Penin, F.; dubuisson, J.; Rey, F.A.; et al., (2004):** structural biology of hepatitis C Virus. *Hepatology*; 39:5-19

**Perz, J.F.; Armstrong, G.L.; Farrington, L.A.; et al., (2006):** The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 45: 529-538.

**Pestka, S.; Semin, D. and Oncol, I. (1997):** The human interferon-alpha species and hybrid proteins . *Semin Oncol*; 24(suppl): 9-17. plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*; 358: 958-965.

**Pockros, P.J.; Jeffers, L.; Afdhal, N.; et al., (2007):** Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of



interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. *Hepatology*;45(3):569-78.

**Pockros, P.J.; Patel, K.; O'Brien, C.; et al., (2003):** A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. *Hepatology.* ;37(6):1368-74.

**Poller, L. (1986):** Laboratory control of anticoagulant therapy. *Sem Thromb Hemostasis*, 12:13-9.

**Powell, E.E.; Jonsson, J.R. and Clouston, A.D. (2005):** Steatosis: co-factor in other liver diseases. *Hepatology*; 42: 5-13.

**Poynard, T.; Ratziu, V.; McHutchison, J.; et al., (2003):** Effect of treatment with peg-interferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology*; 38: 75-85.

**Pradat, P.; Alberti, A.; Poynard, T.; et al., (2002):** Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. *Hepatology*; 36: 973–977.

**Raison, C.L.; Demetrashvili, M.; Capuron, L.; et al., (2005):** Neuro psychiatric adverse effects of interferon-alpha: recognition and management. *CNS Drugs*; 19: 105-123.

**Regev, A.; Berho, M.; Jeffers, L.J.; et al., (2002):** Sampling error and intra observer variation in liver biopsy in patients with chronic HCV infection. *Am. J. Gastroenterol.*; 97: 2614-2618.

**Rehermann, B. (2000):** Immunopathogenesis of hepatitis C. In: *Hepatitis C* Liang Tj and Hoofnagle JH (eds.), Academic press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto, ch. (8): 147-168.



**Reiser, M.; Marotzsis, C.G.; Nelson, D.R.; et al., (1997):** Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. *J Hepatol*; 26: 471- 478.

**Reiss, G. and Keeffe, E.B. (2005):** Role of liver biopsy in the management of chronic liver disease: selective rather than routine. *Rev Gastroenterol. Disord.*; 5: 195-205.

**Roberts, E.A. and Yeung, L. (2002):** Maternal-infant transmission of hepatitis C virus infection. *Hepatology* 36: S106-S113

**Rockey, D.C. and Bissell, D.M. (2006):** Non invasive measures of liver fibrosis. *Hepatology*; 43 (Suppl): S113-S120.

**Rodés, J. and Sánchez Tapias, J.M. (2000):** Hepatitis C. *Nephrol Dial Transplant*; 15(suppl 8):2-11.

**Rodriguez-Torres, M.; Lawitz, E.; Godofsky, E.; et al., (2005):** Valopicitabine (nm283) alone and in combination with peg-interferon in patients with genotype 1 chronic hepatitis C: preliminary results from an ongoing phase II, multicenter study [abstract]. *Gastroenterology*; 128(suppl12): A-695-A-696.

**Romero-Gomez, M.; Del Mar Vilorio, M.; Andrade, R.J.; et al., (2005):** Insulin resistance impairs sustained response rate to peg-interferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*; 128: 636-641.

**Ross, A. and Chung, R.T. (2004):** “Natural history of acute hepatitis C in U.S. cohort. Abstract of Digestive Disease Week. New Orleans, Louisiana. (abstract 105779).



**Saab, S.; Martin, P.; Brezina, M.; et al., (2001):** Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. *Am J Kidney Dis* 37: 308- 15.

**Sagir, A.; Erhardt, A.; Schmitt, M.; et al., (2008):** Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. *Hepatology*; 47: 592-595.

**Santolini, F.; Migliaccio, G. and La Monica, N. (1994):** Biosynthesis and biochemical properties of the hepatitis C virus core protein. I *Virology*, 68: 3631- 3641.

**Sarna, G.; Pertcheck, M. and Figlin, R. ( 1986):** Phase I study of recombinant beta ser 17 interferon in the treatment of cancer. *Cancer Treat Rep*;70:1365-1372.

**Sarrazin, C.; Rouzier, R.; Wagner, F.; et al., (2007):** SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. *Gastroenterology*. ; 132(4):1270-8.

**Schott, E.; Witt, H.; Neumann, K.; et al., (2007):** A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. *J Hepatol.*; 47(2):203-11

**Scott, J.D. and Gretch, D.R. (2007):** Molecular diagnostics of hepatitis C virus infection: a systematic review. *JAMA* 297: 724-32.

**Seeff, L.B. and Hoofnagle, J.H. (2002):** National Institutes of Health Consensus Development Conference Management of hepatitis C. *Hepatology*; 36 (Suppl): S1-S2.



**Shepard, C.W.; Finelli, L. and Fiore, A.E. (2005):** Epidemiology of hepatitis B and hepatitis B virus infection in United States children. *Pediatr Infect Dis J* 24: 755-760.

**Shiffman, M.L.; Salvatore, J.; Hubbard, S.; et al., (2007):** Treatment of chronic hepatitis C virus genotype 1 with peg-interferon plus ribavirin. *Hepatology*; 46: 371-379.

**Shindo, M.; Arai, K. and Sokawa, Y. (1995):** The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. *Hepatology*; 22: 418 -425.

**Silver, H.K.B.; Deneault, J.; Gold, P.; et al., (1974):** The detection of alpha-fetoprotein in patients with viral hepatitis. *Cancer Res.*; 34: 244-247.

**Simmonds, P.; Albert, A.; Alter, H.J.; Bonino, F.; et al., (1994 a):** a proposed system for the nomenclature of hepatitis C virus viral genotypes. *Hepatology* ; 19:1321-1324.

**Simmonds, P.; Bukh, J.; Combet, C.; et al., (2005):** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*; 42: 962-973.

**Simmonds, P.; Smith, D.P.; Mc Omish, F.; et al., (1994b):** identification of genotypes of hepatitis C virus by sequence comparisons in core, E1 and N55 region. *J Gen Virol*;75: 1053-1061.

**Soza, A.; Everhart, J.E.; Ghany, M.G.; et al., (2002):** Neutropenia during combination therapy of interferon Alfa and ribavirin for chronic hepatitis C. *Hepatology*; 36: 1273-1279.



**Sreevalsan, T. and Hellman, S.M. (1995):** Biological therapy with Interferon-alfa and beta: preclinical studies. In: DeVita VTJ, Rosenberg SA, eds. *Biologic Therapy of Cancer*; Second Ed: 347-364.

**Stark, G.R; Kerr, I.M; Williams, B.R; et al., (1998):** How cells respond to interferons. *Annu. Rev. Biochem.* ;67:227-264.

**Sulkowski, w.; Karges, H. and Manthey, F. (2000) :** Growth inhibition of human lymphoblastoid Daudi cells in vitro by interferon preparations. *Archives of Virology*;51:87-97.

**Takano, S.; Ito, Y.; Yokosuka, O.; Ohto, M.; et al., (1994):** A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. *Hepatology.* ; 20(3):558-64.

**Taketa, K. (1990):** Alfa-fetoprotein: reevaluation in hepatology. *Hepatology*; 12: 1420–1432.

**Takikawa, Y. and Suzuki, K. (2002):** Is AFP a new reliable marker of liver regeneration in acute hepatic failure? *J. Gastroenterol.*; 37: 681–682.

**Taliani, G.; Gemignani, G.; Ferrari, C.; et al., (2006):** Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon- ribavirin non-responder patients. *Gastroenterology*; 130: 1098-1106.

**Taniguchi, N.; Lizuka, S.; Yokosawa, N.; et al., (2004):** Measurement of human serum immunoreactive  $\gamma$ -glutamyltranspeptidase in patients with malignant tumors using enzyme-linked immunoassay. *Cancer Res.*; 45: 5835-5839.



**Tanji, Y.; Kaneko, T.; Satoh, S. and Shimotohno, K. (1995):** Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. *J Virol*; 69: 3980-6.

### **Tanaka**

**Teuber, G.; Pascu, M.; Berg, T.; et al., (2003):** Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. *J Hepatol.*; 39(4):606-13.

**The Lasker Foundation (2008):** 2000 Winners Albert Lasker Award for Clinical Medical Research. The role of parenteral antischistosomal therapy in the spread of HCV in Egypt. *Lancet*; 355: 887-891. The role of parenteral antischistosomal therapy in the spread of HCV in Egypt. *lancet* ;355:887-891.

**Thomas, D.L. and Seeff, L.B. (2005):** Natural history of hepatitis C. *Clin. Liver Dis.*; 9: 383-398, vi.

**Thomson, M. and Liang, T.J. (2000):** Molecular biology of hepatitis C: hepatitis C. Liang TJ and Hoofnagle JH (eds). Academic press, San Diego, London, Boston, Tokyo, Toronto, ch. (1): 1-23.

**Thorpe, L.E.; Ouellet, L.J.; Hershov, R.; et al., (2002):** Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. *Am J Epidemiol* 155: 645-653.

**Thuluvath, P.J.; Maheshwari, A.; Mehdi, J.; et al., (2004):** Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. *Gut.*; 53(1):130-5.



**Tong, M.; El-Farra, N.S.; Reikes, A.R.; et al., (1995):** Clinical outcomes after transfusion associated hepatitis C. *N. Engl. J. Med.*; 332: 1463–1436.

**Vajdy, M.; Selby, M.; Medina-Selby, A.; et al., (2006):** Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. *J Gen Virol.*; 87(Pt 8):2253-62.

**Veldt, B.J.; Heathcote, E.J.; Wedemeyer, H.; et al., (2007):** SVR and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann. Intern. Med.*; 147: 677-684.

**Vogt, M.; Lang, T.; Frosner, G.; et al., (1999):** Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *N. Engl. J. Med.*; 341: 866-870.

**Von Herbay, A.; Stahl, W. and Niederau, C. ( 1997):** Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. *Free Radic Res.*; 27(6):599-605.

**Watanabe, Y. (2004):** Fifty Years of Interferons”. *Nature Immunology* ; 5(12): 1193-99.

**Weinberg, D.S. and Malet, P.F. (1994):** Chronic hepatitis C and markedly elevated serum alpha-fetoprotein: complete response to treatment with alpha interferon. *Am. J. Gastroenterol.*; 89: 1253–1254.

**Wills, R.J. (1990):** Clinical pharmacokinetics of interferons. *Clin Pharmacokinet*; 19: 390-399.



**Wreghitt, T.G. (1999):** Blood-borne virus infections in dialysis units--a review. *Rev Med Virol* 9: 101-9.

**Yang, S.S.; KS Cheng, Y.C.; Lai, et al., (2002):** Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. *J. Gastroenterol.* 37: pp. 626–632.

**Yano, M.; Kumada, H.; Hashimoto, E.; et al., (1996):** The long-term pathological evolution of chronic hepatitis C. *Hepatology*; 23: 1334-1340.

**Yao, F.Y. (2003):** Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. *J. Clin. Gastroenterol.*; 36: 440–442.

**Yen, T.; Keeffe, E.B. and Ahmed, A. (2003):** The epidemiology of hepatitis C virus infection. *J Clin Gastroenterol*; 36: 47- 53.

**Zacks, S.L. and Fried, M.W. (2001):** Hepatitis B and C and renal failure. *Infect Dis Clin North Am* 15:877–899.

**Zeuzem, S.; Buti, M.; Ferenci, P.; et al., (2000):** Efficacy of 24 weeks treatment with peg-interferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J. Hepatol.*; 44: 97-103.

**Zeuzem, S.; Welsch, C. and Herrmann E. (2003):** Pharmacokinetics of peg-interferons. *Semin. Liver Dis.*; 23(Suppl 1): 23-28.

**Zeuzem, S.; Yoshida, E.M.; Benhamou, Y.; et al., (2008):** Sustained virologic response rates with albinterferon alfa-2B plus ribavirin treatment in IFN-naive chronic hepatitis C genotype 1 patients. *Hepatology.*; 48(2):407-17.

**Zhang, P.; Wu, C.G.; Mihalik, K.; et al., (2007):** Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. *Proc Natl Acad Sci U S A.*; 104(20):8449-54.

**Zhou, A.; Hassel, B.A. and Silverman, R.H. (1993):** Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. *Cell Immunol*; 72:753-765.